DIAGNOSTIC LABORATORY SERVICES, INC.

Antimicrobial Susceptibility Profile (January 2020 - December 2020)
Outpatient Only

NOTE: Statistics include data from patients seen in the medical centers through the Emergency Department, Ambulatory and Clinics.

GRAM NEGATIVE SUSCEPTIBILITIES (Percent Susceptible)

Cefazolin (urine) limited to *E. coli, K.pneumoniae* and *P.mirabilis*	*Achromobacter xylosoxidans*		*Acin.baumannii complex* [a]		*Citro. freundii* complex [b]		*Citrobacter koserii*		*Klebsiella (Ent) aerogenes* [c]		*Ent. cloacae* complex [d]		*Escherichia coli*		*E. coli* (ESBL)		*Klebsiella oxytoca*		*Klebsiella pneumoniae*		*Kleb pneumo* (ESBL)		*Klebsiella variicola*		*Morganella morganii*		*Proteus hauseri*		*Proteus mirabilis*		*Providencia rettgeri*		*Pseudo aeruginosa*		*Serratia marcescens*	
	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun (3 ESBL)	Jul-Dec (7 ESBL)	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun (11 ESBL)	Jul-Dec (8 ESBL)	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec
Amikacin	*	26			100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
Ampicillin													63	65															89	91						
Ampicillin/Sulbactam			100	100									82	83			84	93	92	93			100	98	19	9	79	69	96	98	52	90				
Cefazolin (urine)													97	97					99	99			100	n/a					98	98						
Cefepime	*	38	97	99	99	100	100	100	100	99	97	94	100	100			100	100	100	100			100	97	100	100	100	100	100	100	90	100	100	97	99	99
Ceftazidime	*	80	n/a	99																													n/a	96		
Ceftriaxone	*	22	91	92	87	86	98	99	88	92	82	84	99	99			99	100	100	100					95	99	92	88	99	100	88	100			98	99
Ciprofloxacin	*	47	97	97	93	92	98	99	97	97	93	93	84	84	15	15	93	96	96	96	15	15	98	94	89	89	97	97	93	95	75	84	100	90	99	89
Ertapenem					100	100	100	100	99	100	97	100	100	100	100	100	100	100	100	100	99	99	100	100	100	100	100	100	100	100	100	100			100	100
Gentamicin	*	16	100	100	92	98	99	100	100	100	97	95	94	95	82	79	100	100	100	100	61	67	100	100	94	97	100	100	98	98	100	100	100	99	100	100
Imipenem	*	100	100	100											100	100					100	99											100	93		
Levofloxacin	*	95	n/a	99	n/a	92	n/a	100	n/a	97	n/a	97	n/a	85	n/a	11	n/a	99	n/a	98	n/a	16	n/a	97	n/a	91	n/a	100	n/a	96	n/a	83			n/a	91
Nitrofurantoin (urine)					97	100	99	98	50	22	75	66	99	99	99	98	100	96	71	61	40	23	90	87												
Piperacillin/Tazobactam	*	100	96	93	96	96	100	100	92	93	86	90	99	99	98	98	96	99	99	99	89	50	100	100	100	100	100	100	100	50	94	100	100	99		
Tobramycin	*	17	100	100	93	100	100	100	100	99	98	95	99	99	90	91	100	100	100	100	51	54	100	100	100	99	100	100	99	99	100	100	100	100	100	99
Trimeth-Sulfa	*	94	90	90	86	89	99	100	99	97	85	85	81	82	45	42	95	95	94	94	7	14	100	97	90	92	92	91	80	92	75	81			100	99
Total Isolates	23	50	30	148	71	82	195	233	175	176	193	245	7112	7487	756	779	78	77	1391	1588	121	118	61	69	109	139	38	34	662	948	32	32	827	1240	101	95
													ESBL Rates		10%	9%	4%	8%			8%	7%							2%	1%						

a *Acinetobacter baumanni* complex includes *A.calcoacecus, A.baumannii, A.dijkshoomiae, A.nosocomialis, A.pittii* and *A. seifertii*

b *Citrobacter freundii* complex includes *C.braaki, C.freundii, C.gillenii, C.murliniae, C.rodenticum, C.sedlakii* and *C.wekmenii*

c *Enterobacter aerogenes* has been renamed *Klebsiella aerogenes*

d *Enterobacter cloacae* complex includes *E.asburiae, E.cancerogenus, E.cloacae, E.dissolvens, E.hormaechei, E.kobei* and *E.nimipressuralis*

GRAM POSITIVE SUSCEPTIBILITIES (Percent Susceptible)

S.aureus complex includes *S.aureus, S.argenteus* and *S.schweitzeri*	*S,aureus* [3] complex MSSA [4]		*S. aureus* [3] complex MRSA		*Staph* sp. [3] (coag neg)		*Enterococcus* Non-VRE [5]		*Enterococcus* VRE		*Streptococcus agalactiae*		*Streptococcus pneumoniae*		*Streptococcus pyogenes*	
	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec
Ampicillin							97	98	*	*						
Cefazolin	100	100			57	60										
Cefotaxime													*	*		
Cetriaxone											100	100	See Table		100	100
Ciprofloxacin (urine)							90	90	*	*						
Clindamycin [1, 2]	84	83	61	62	70	70					66	57	*	*	88	87
Daptomycin	100	100	100	100	100	100										
Erythromycin	74	72	23	23	47	50					56	47	*	*	86	85
Levofloxacin (urine)							n/a	91	*	*			*	*		
Linezolid	100	100	100	100	100	100	100	100	*	*						
Minocycline	n/a	100	n/a	99	n/a	100										
Moxifloxacin	96	96	60	52	78	81										
Nitrofurantoin (urine)	100	100	100	100	100	100	99	99	*	*						
Oxacillin	100	100			58	60										
Penicillin	37	38			23	26					100	100	See Table		100	100
Rifampin [3]	100	100	100	99	98	99										
Tetracycline [6]	94	92	82	81	83	82	28	24	*	*			*	*		
Trimeth-Sulfa	97	97	62	61	74	79							*	*		
Vancomycin	100	100	100	100	100	100	99	99	*	*	100	100	*	*	100	100
Total Isolates	1703	1954	839	1139	792	1039	833	1262	28	24	82	91	24	7	737	911
	MRSA Rate		33%	37%			VRE Rate		3%	2%						

Footnotes:

[1] Clindamycin & Erythromycin are not appropriate for urine sources

[2] Erythromycin is not appropriate for pregnant women

[3] Rifampin should not be used alone for treatment of *Staph* infections

[4] *Staph aureu* s (MSSA) isolates that show Penicillin susceptibility may harbor the blaZ gene that produces beta-lactamase.

[5] Non-VRE includes intrnsically resistant *Enterococcus* (*E. casseliflavus* & *E.gallinarum*)

[6] For urine only with isolates of *Enterococcus*

Streptococcus pneumoniae					
Ceftriaxone			Peniclin		
MIC	# isolates S.pneumoniae		MIC	# isolates S.pneumoniae	
	Jan-Jun	Jul-Dec		Jan-Jun	Jul-Dec
<=0.12	*	*	<=0.06	*	*
0.25	*	*	0.12	*	*
0.5	*	*	0.25	*	*
1	*	*	0.5	*	*
2	*	*	1	*	*
>=4	*	*	2	*	*
			4	*	*
			>=8	*	*

S. pneumoniae interpretive guidelines

Penicillin		
Parenteral non-meningitis		
<=2 S	4 I	>=8 R
Parenteral meningitis		
<=0.06 S	----	>=0.12 R
Oral		
<=0.06 S	0.12-1 I	>=2 R
Ceftriaxone		
Non-meningitis		
<=1 S	2 I	>=4 R
Meningitis		
<=0.5 S	1 I	>=2 R

Stenotrophomonas maltophilia	Jan-Jun	Jul-Dec
Levofloxacin	*	84
Trimethoprim/Sulfa	*	94
Ceftazidime *	*	43
Total Isolates	27	70

* Ceftazidime resulted if Trimeth/Sulfa is Resistant

Haemophilus influenzae	Jan-Jun	Jul-Dec
Ampicillin	75	*
Azithromycin	100	*
Cetriaxone	100	*
Cefuroxime	93	*
Meropenem	100	*
Moxifloxacin	100	*
Tetracycline	90	*
Total Isolates	63	17

Asterisk (*) indicates no result available

Where isolates in both periods are >=30, the following apply:

Green indicates increase in susceptibility by >5%

Red indicates decrease in susceptibility by >5%

NOTE: Where total isolates is less than 30, the susceptibility percentage may not be clinicall significant and are highlighted in BLUE on these tables.
Source: CLSI Document M39-A4, January 2014

Data compiled by the Microbiology Department at Diagnostic Laboratory Services, Inc. January 2021 (c)